GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Selling, General, & Admin. Expense

Brii Biosciences (HKSE:02137) Selling, General, & Admin. Expense : HK$62.46 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Brii Biosciences's selling, general, & admin. expense for the six months ended in Dec. 2023 was HK$27.43 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$62.46 Mil.


Brii Biosciences Selling, General, & Admin. Expense Historical Data

The historical data trend for Brii Biosciences's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Selling, General, & Admin. Expense Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
25.09 41.40 57.76 89.70 62.46

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only 37.54 47.67 44.29 35.03 27.43

Competitive Comparison of Brii Biosciences's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Brii Biosciences's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brii Biosciences's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's Selling, General, & Admin. Expense falls into.



Brii Biosciences Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$62.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Brii Biosciences  (HKSE:02137) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Brii Biosciences Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Brii Biosciences (HKSE:02137) Business Description

Industry
Traded in Other Exchanges
Address
No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Executives
Hong Zhi 2101 Beneficial owner
Xyxy Holdings Ltd. 2201 Interest of corporation controlled by you
Booming Passion Limited 2101 Beneficial owner
Boyu Capital Fund Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd 2201 Interest of corporation controlled by you
Tong Xiaomeng 2201 Interest of corporation controlled by you
Boyu Group, Llc 2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Invesco Advisers, Inc. 2102 Investment manager
Ma Yun 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yf Bright Insight Limited 2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines